US20040141983A1
(en)
*
|
1999-03-15 |
2004-07-22 |
Protein Design Labs, Inc. |
Compositions against cancer antigen LIV-1 and uses thereof
|
US20040018194A1
(en)
*
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
US7256257B2
(en)
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
EP2335728A1
(en)
|
2001-05-11 |
2011-06-22 |
Ludwig Institute for Cancer Research Ltd. |
Specific binding proteins and uses thereof
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
KR20030033007A
(ko)
*
|
2001-05-31 |
2003-04-26 |
코울터 파머수티컬, 인코포레이티드 |
세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
|
US20110045005A1
(en)
|
2001-10-19 |
2011-02-24 |
Craig Crowley |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
SG108837A1
(en)
*
|
2002-03-11 |
2005-02-28 |
Pi Eta Consulting Co Pte Ltd |
An enterprise knowledge and information acquisition, management and communications system with intelligent user interfaces
|
DK1545613T3
(da)
*
|
2002-07-31 |
2011-11-14 |
Seattle Genetics Inc |
Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
|
WO2004067564A2
(en)
|
2003-01-29 |
2004-08-12 |
Protein Design Labs, Inc. |
Compositions against cancer antigen liv-1 and uses thereof
|
US20080025989A1
(en)
*
|
2003-02-20 |
2008-01-31 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
ES2347959T3
(es)
*
|
2003-02-20 |
2010-11-26 |
Seattle Genetics, Inc. |
Conjugados de anticuerpos anti-cd70-farmaco y su uso para el tratamiento del cancer.
|
RU2448117C2
(ru)
*
|
2003-11-06 |
2012-04-20 |
Сиэтл Дженетикс, Инк. |
Монометилвалиновые соединения, способные образовывать конъюгаты с лигандами
|
NZ583292A
(en)
|
2003-11-06 |
2012-03-30 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
US20050175619A1
(en)
*
|
2004-02-05 |
2005-08-11 |
Robert Duffy |
Methods of producing antibody conjugates
|
ES2533695T3
(es)
*
|
2004-03-02 |
2015-04-14 |
Seattle Genetics, Inc. |
Anticuerpos cargados parcialmente y métodos para su conjugación
|
US7691962B2
(en)
*
|
2004-05-19 |
2010-04-06 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
CN102973947A
(zh)
|
2004-06-01 |
2013-03-20 |
健泰科生物技术公司 |
抗体-药物偶联物和方法
|
US7973134B2
(en)
*
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
BRPI0516284A
(pt)
|
2004-09-23 |
2008-09-02 |
Genentech Inc |
anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
|
US7935790B2
(en)
*
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
CA2583208C
(en)
*
|
2004-10-15 |
2015-08-25 |
Seattle Genetics, Inc. |
Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
US8337838B2
(en)
*
|
2004-10-15 |
2012-12-25 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
US7641903B2
(en)
*
|
2004-10-15 |
2010-01-05 |
Seattle Genetics, Inc. |
Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
|
ES2715776T3
(es)
*
|
2004-11-12 |
2019-06-06 |
Seattle Genetics Inc |
Auristatinas que tienen una unidad de ácido aminobenzoico en el extremo N
|
DE602005022928D1
(de)
|
2004-11-30 |
2010-09-23 |
Abgenix Inc |
Antikörper gegen gpnmb und ihre verwendungen
|
US7807789B2
(en)
*
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
ES2386366T3
(es)
*
|
2005-02-18 |
2012-08-17 |
Medarex, Inc. |
Anticuerpo monoclonal humano contra el antígeno de membrana específico de la próstata (PSMA)
|
EP1871911A2
(en)
|
2005-04-07 |
2008-01-02 |
Chiron Corporation |
Cancer-related genes (prlr)
|
AU2006235276A1
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
CACNA1E in cancer diagnosis, detection and treatment
|
US7714016B2
(en)
*
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
US20090099340A1
(en)
*
|
2007-10-12 |
2009-04-16 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
ES2477765T3
(es)
|
2005-04-19 |
2014-07-17 |
Seattle Genetics, Inc. |
Agentes de unión al anti-cd70 humanizado y usos de los mismos
|
WO2006111169A1
(en)
*
|
2005-04-21 |
2006-10-26 |
Gastrotech Pharma A/S |
Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
|
PT1912677E
(pt)
*
|
2005-06-20 |
2013-12-23 |
Psma Dev Company L L C |
Conjugados de anticorpos contra psma-fármaco
|
WO2007008848A2
(en)
|
2005-07-07 |
2007-01-18 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
|
ES2708763T3
(es)
|
2005-07-07 |
2019-04-11 |
Seattle Genetics Inc |
Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
|
PL1912671T3
(pl)
|
2005-07-18 |
2018-02-28 |
Seattle Genetics, Inc. |
Koniugaty beta-glukuronid-linker-lek
|
WO2007027906A2
(en)
*
|
2005-08-31 |
2007-03-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
US20100151495A9
(en)
*
|
2005-08-31 |
2010-06-17 |
Cell Signaling Technolgy, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
JP5290756B2
(ja)
*
|
2005-09-26 |
2013-09-18 |
メダレックス インコーポレイテッド |
抗体−薬剤コンジュゲート及びその使用
|
US7847105B2
(en)
|
2005-10-26 |
2010-12-07 |
Medarex, Inc. |
Methods and compounds for preparing CC-1065 analogs
|
WO2007059404A2
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
RU2426742C2
(ru)
|
2005-12-02 |
2011-08-20 |
Дженентек, Инк. |
Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами
|
AR057237A1
(es)
|
2005-12-15 |
2007-11-21 |
Genentech Inc |
Metodos y composiciones para actuar sobre la poliubiquitina
|
CN103360496B
(zh)
|
2006-01-05 |
2015-11-18 |
健泰科生物技术公司 |
抗ephb4抗体及其使用方法
|
JP5368110B2
(ja)
|
2006-01-20 |
2013-12-18 |
ジェネンテック, インコーポレイテッド |
抗エフリンb2抗体とその使用方法
|
US7750116B1
(en)
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
SG170728A1
(en)
|
2006-03-23 |
2011-05-30 |
Novartis Ag |
Anti-tumor cell antigen antibody therapeutics
|
AU2007238636A1
(en)
|
2006-04-13 |
2007-10-25 |
Novartis Vaccines & Diagnostics, Inc. |
Methods of treating, diagnosing or detecting cancer
|
US20090298093A1
(en)
*
|
2006-04-27 |
2009-12-03 |
Roberto Polakiewicz |
Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways
|
SG10201501103RA
(en)
|
2006-05-30 |
2015-04-29 |
Genentech Inc |
Antibodies And Immunoconjugates And Uses Therefor
|
US7939636B2
(en)
*
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
US20090258442A1
(en)
*
|
2006-08-31 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
CA2662236A1
(en)
|
2006-09-12 |
2008-03-20 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of cancer
|
ES2636089T3
(es)
|
2006-10-27 |
2017-10-05 |
Genentech, Inc. |
Anticuerpos e inmunoconjugados y usos para los mismos
|
PL2099823T5
(pl)
|
2006-12-01 |
2023-02-20 |
Seagen Inc. |
Wariant środków wiążących cel i jego zastosowania
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
CN104043123B
(zh)
|
2007-01-25 |
2019-08-13 |
达娜-法勃肿瘤研究所公司 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
US7834154B2
(en)
|
2007-02-09 |
2010-11-16 |
Genentech, Inc. |
Anti-ROBO4 antibodies and uses therefor
|
KR20090122439A
(ko)
|
2007-02-21 |
2009-11-30 |
메다렉스, 인코포레이티드 |
단일 아미노산을 갖는 화학적 링커 및 이의 접합체
|
US20090081659A1
(en)
|
2007-03-07 |
2009-03-26 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
EP2125898B1
(en)
|
2007-03-14 |
2013-05-15 |
Novartis AG |
Apcdd1 inhibitors for treating, diagnosing or detecting cancer
|
CN101688229B
(zh)
*
|
2007-03-15 |
2013-06-12 |
路德维格癌症研究所 |
包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
EP1975184A3
(en)
|
2007-03-26 |
2008-11-26 |
Cell Signaling Technology, Inc. |
Serine or threonine phosphorylation sites
|
US20080238709A1
(en)
*
|
2007-03-28 |
2008-10-02 |
Faramarz Vaziri |
One-way communication apparatus with dynamic key generation
|
EP1983002A3
(en)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
EP1983003A3
(en)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
JP5290276B2
(ja)
|
2007-05-08 |
2013-09-18 |
ジェネンテック, インコーポレイテッド |
システイン改変抗muc16抗体および抗体−薬物結合体
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
EP2641618A3
(en)
|
2007-07-16 |
2013-10-23 |
Genentech, Inc. |
Humanized anti-CD79B antibodies and immunoconjugates and methods of use
|
AR067544A1
(es)
|
2007-07-16 |
2009-10-14 |
Genentech Inc |
Anticuerpos anti- cd79b e inmunoconjugados y metodos de uso de los mismos
|
US20090035848A1
(en)
*
|
2007-08-03 |
2009-02-05 |
Robert Hickey |
Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products
|
CN101896503B
(zh)
|
2007-08-14 |
2018-05-22 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
AU2008308509B2
(en)
|
2007-10-04 |
2014-10-23 |
Zymogenetics, Inc. |
B7 family member zB7H6 and related compositions and methods
|
WO2009052249A1
(en)
*
|
2007-10-19 |
2009-04-23 |
Genentech, Inc. |
Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
|
EP2211904B1
(en)
|
2007-10-19 |
2016-08-17 |
Seattle Genetics, Inc. |
Cd19 binding agents and uses thereof
|
EP3115469B1
(en)
|
2007-11-19 |
2020-04-29 |
Celera Corporation |
Lung cancer markers and uses thereof
|
EP2062920A3
(en)
|
2007-11-21 |
2009-06-17 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
WO2009092011A1
(en)
|
2008-01-18 |
2009-07-23 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
SG187517A1
(en)
|
2008-01-31 |
2013-02-28 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
US20090220991A1
(en)
*
|
2008-02-29 |
2009-09-03 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
NO2842575T3
(US20080131398A1-20080605-C00009.png)
*
|
2008-03-18 |
2018-02-24 |
|
|
US20090258013A1
(en)
|
2008-04-09 |
2009-10-15 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
EP2274437B1
(en)
|
2008-04-10 |
2015-12-23 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
KR20210005318A
(ko)
*
|
2008-04-30 |
2021-01-13 |
이뮤노젠 아이엔씨 |
가교제 및 그 용도
|
AU2009242453B2
(en)
|
2008-05-02 |
2014-12-04 |
Seagen Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
DK2318832T3
(da)
|
2008-07-15 |
2014-01-20 |
Academia Sinica |
Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
|
US8148088B2
(en)
*
|
2008-07-18 |
2012-04-03 |
Abgent |
Regulation of autophagy pathway phosphorylation and uses thereof
|
EP2326350B1
(en)
|
2008-09-08 |
2013-09-04 |
Psma Development Company, L.L.C. |
Compounds for killing psma-expressing, taxane-resistant cancer cells
|
WO2010039832A1
(en)
|
2008-10-01 |
2010-04-08 |
Genentech, Inc. |
Anti-notch2 antibodies and methods of use
|
EP4378482A2
(en)
|
2009-01-09 |
2024-06-05 |
Seagen Inc. |
Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
|
WO2010096394A2
(en)
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
EP2408817B1
(en)
|
2009-03-20 |
2016-03-16 |
F.Hoffmann-La Roche Ag |
Bispecific anti-her antibodies
|
BRPI1006448B1
(pt)
|
2009-03-25 |
2021-08-17 |
Genentech, Inc |
Anticorpo antagonista anti-fgfr3, anticorpo monoclonal, polinucleotídeo, vetor, microorganismo transgênico, método para produção de um anticorpo anti-fgfr3, formulação farmacêutica e usos do anticorpo antagonista anti-fgfr3
|
CA2756988A1
(en)
|
2009-04-01 |
2010-10-07 |
Genentech, Inc. |
Anti-fcrh5 antibodies and immunoconjugates
|
PE20120878A1
(es)
|
2009-04-01 |
2012-08-06 |
Genentech Inc |
ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
|
JP5501439B2
(ja)
|
2009-04-02 |
2014-05-21 |
ロシュ グリクアート アクチェンゲゼルシャフト |
完全長抗体と単鎖Fabフラグメントとを含む多重特異的抗体
|
US20120135005A1
(en)
|
2009-04-16 |
2012-05-31 |
Harding Fiona A |
ANTI-TNF-a ANTIBODIES AND THEIR USES
|
CN106117348A
(zh)
|
2009-06-04 |
2016-11-16 |
诺华公司 |
识别IgG结合位点的方法
|
MX2011013781A
(es)
|
2009-06-17 |
2012-05-29 |
Abbott Biotherapeutics Corp |
Anticuerpos anti-vegf y sus usos.
|
BRPI1015234A2
(pt)
|
2009-06-22 |
2018-02-20 |
Medimmune Llc |
regiões fc projetadas para conjugação sítio específica.
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
AU2010289400B2
(en)
|
2009-09-02 |
2014-10-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
US20110070248A1
(en)
*
|
2009-09-24 |
2011-03-24 |
Seattle Genetics, Inc. |
Dr5 ligand drug conjugates
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
HUE026447T2
(en)
|
2009-10-16 |
2016-05-30 |
Novartis Ag |
Pharmacodynamic tumor response biomarkers
|
TW201121566A
(en)
|
2009-10-22 |
2011-07-01 |
Genentech Inc |
Anti-hepsin antibodies and methods using same
|
EA201792376A3
(ru)
|
2009-10-23 |
2018-08-31 |
Милленниум Фармасьютикалз, Инк. |
Молекулы анти-gcc антитела и соответствующие композиции и способы
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
US8658175B2
(en)
|
2009-10-28 |
2014-02-25 |
Abbvie Biotherapeutics Inc. |
Anti-EGFR antibodies and their uses
|
NZ598901A
(en)
|
2009-11-05 |
2014-08-29 |
Genentech Inc |
Methods and composition for secretion of heterologous polypeptides
|
MX338694B
(es)
|
2009-11-30 |
2016-04-27 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores.
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
CN102770456B
(zh)
|
2009-12-04 |
2018-04-06 |
弗·哈夫曼-拉罗切有限公司 |
多特异性抗体、抗体类似物、组合物和方法
|
MX2012006443A
(es)
|
2009-12-09 |
2012-06-28 |
Inst Nat Sante Rech Med |
Anticuerpos monoclonales que se enlazan a b7h6 y usos de los mismos.
|
ES2565208T3
(es)
|
2009-12-11 |
2016-04-01 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-VEGF-C y métodos de uso de los mismos
|
WO2011084496A1
(en)
|
2009-12-16 |
2011-07-14 |
Abbott Biotherapeutics Corp. |
Anti-her2 antibodies and their uses
|
DK2516465T3
(en)
|
2009-12-23 |
2016-06-06 |
Hoffmann La Roche |
ANTI-BV8 ANTIBODIES AND APPLICATIONS THEREOF
|
CA2789230C
(en)
|
2010-02-08 |
2019-04-02 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to 161p2f10b proteins
|
CN102985113B
(zh)
|
2010-02-23 |
2015-05-20 |
霍夫曼-拉罗奇有限公司 |
用于肿瘤诊断和治疗的组合物和方法
|
KR20130049775A
(ko)
|
2010-03-12 |
2013-05-14 |
애브비 바이오테라퓨틱스 인크. |
Ctla4 단백질 및 이의 용도
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
UA107827C2
(en)
|
2010-03-31 |
2015-02-25 |
Boehringer Ingelheim Int |
Antibody cd40
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
EA024730B1
(ru)
|
2010-04-15 |
2016-10-31 |
Медимьюн Лимитед |
Пирролбензодиазепиновые соединения, их конъюгаты, фармацевтические композиции, содержащие указанные конъюгаты, и применение указанных конъюгатов
|
TWI586806B
(zh)
|
2010-04-23 |
2017-06-11 |
建南德克公司 |
異多聚體蛋白質之製造
|
KR20130079384A
(ko)
|
2010-05-03 |
2013-07-10 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 조성물 및 방법
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
NZ701208A
(en)
|
2010-06-03 |
2016-05-27 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses thereof
|
KR101839163B1
(ko)
|
2010-06-08 |
2018-03-15 |
제넨테크, 인크. |
시스테인 조작된 항체 및 접합체
|
ES2528956T3
(es)
|
2010-06-10 |
2015-02-13 |
Seattle Genetics, Inc. |
Nuevos derivados de auristatina y su uso
|
AU2011283694B2
(en)
|
2010-07-29 |
2017-04-13 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
CA2807278A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann - La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
UA110495C2
(en)
|
2010-09-29 |
2016-01-12 |
Agensys Inc |
Antibody drug conjugates (adc's) that bind to 191p4d12 protein
|
CN103379912B
(zh)
|
2010-09-29 |
2016-03-16 |
西雅图基因公司 |
正羧烷基耳他汀及其应用
|
US9228023B2
(en)
|
2010-10-01 |
2016-01-05 |
Oxford Biotherapeutics Ltd. |
Anti-ROR1 antibodies and methods of use for treatment of cancer
|
AU2011312205B2
(en)
|
2010-10-05 |
2015-08-13 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
EP3581206A1
(en)
|
2010-10-22 |
2019-12-18 |
Seattle Genetics, Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the p13k-akt mtor pathway
|
US9228026B2
(en)
|
2010-12-06 |
2016-01-05 |
Seattle Genetics, Inc. |
Humanized antibodies to LIV-1 and use of same to treat cancer
|
US8911732B2
(en)
|
2010-12-20 |
2014-12-16 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
CN103415621A
(zh)
|
2011-01-14 |
2013-11-27 |
雷德伍德生物科技股份有限公司 |
醛标记免疫球蛋白多肽及其使用方法
|
AR085138A1
(es)
|
2011-02-04 |
2013-09-11 |
Genentech Inc |
VARIANTES DE Fc Y METODOS PARA SU PRODUCCION
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
US9029406B2
(en)
|
2011-03-16 |
2015-05-12 |
Seattle Genetics, Inc |
N-carboxyalkylauristatins and use thereof
|
JP6161592B2
(ja)
|
2011-03-30 |
2017-07-12 |
アリゾナ・ボード・オブ・リージェンツ, フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステート・ユニバーシティArizona Board Of Regents, For And On Behalf Of Arizona State University |
オーリスタチンチラミンリン酸塩およびオーリスタチンアミノキノリン誘導体ならびにそのプロドラッグ
|
DK2694111T3
(en)
|
2011-04-01 |
2016-10-10 |
Wyeth Llc |
Antibody pharmaceutical conjugates
|
WO2012143497A2
(de)
|
2011-04-21 |
2012-10-26 |
Bayer Intellectual Property Gmbh |
Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
|
JP6196613B2
(ja)
|
2011-05-08 |
2017-09-13 |
レゴケム バイオサイエンシズ, インク.Legochem Biosciences, Inc. |
タンパク質−活性剤コンジュゲートおよびこれを調製するための方法
|
AU2012253610A1
(en)
|
2011-05-09 |
2013-12-12 |
University Of Virginia Patent Foundation |
Compositions and methods for treating cancer
|
EP2522638A1
(en)
|
2011-05-12 |
2012-11-14 |
3B-Fibreglass SPRL |
Reinforcing ribs for bushings tip plate
|
JP2014516960A
(ja)
|
2011-05-19 |
2014-07-17 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) |
抗ヒトher3抗体及びその使用
|
EP3415531B1
(en)
|
2011-05-27 |
2023-09-06 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) - binding proteins
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
RU2617402C2
(ru)
|
2011-06-10 |
2017-04-25 |
Мерсана Терапьютикс, Инк. |
Конъюгаты белок-полимер-лекарственное средство
|
EP2723376B1
(en)
|
2011-06-22 |
2018-12-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-axl antibodies and uses thereof
|
EP2723377B1
(en)
|
2011-06-22 |
2018-06-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-axl antibodies and uses thereof
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
DK2764351T3
(en)
|
2011-09-29 |
2019-01-28 |
Seattle Genetics Inc |
Determination of intact mass of protein-conjugated drug compounds
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
EP3611187A1
(en)
|
2011-10-10 |
2020-02-19 |
Xencor, Inc. |
A method for purifying antibodies
|
PT2750713E
(pt)
|
2011-10-14 |
2016-01-20 |
Genentech Inc |
Pirrolobenzodiazepinas e conjugados das mesmas
|
AR088509A1
(es)
|
2011-10-28 |
2014-06-11 |
Genentech Inc |
Combinaciones terapeuticas y metodos para tratar el melanoma
|
PE20141790A1
(es)
|
2011-11-17 |
2014-11-27 |
Pfizer |
Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos
|
AU2012351685A1
(en)
|
2011-12-14 |
2014-07-03 |
Seattle Genetics, Inc. |
FGFR antibody drug conjugates (ADCs) and the use thereof
|
ES2721882T3
(es)
|
2011-12-23 |
2019-08-06 |
Pfizer |
Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
|
WO2013106485A2
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
CA2862979A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
US20150011736A1
(en)
|
2012-01-20 |
2015-01-08 |
Sea Lane Biotechnologies, Llc |
Binding molecule conjugates
|
CN104105711B
(zh)
|
2012-02-10 |
2018-11-30 |
弗·哈夫曼-拉罗切有限公司 |
单链抗体及其他异多聚体
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
CA2866612C
(en)
|
2012-03-08 |
2018-01-16 |
Halozyme, Inc. |
Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
CN104470544B
(zh)
|
2012-05-01 |
2018-01-12 |
基因泰克公司 |
抗pmel17抗体和免疫缀合物
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
SG10201608904YA
(en)
|
2012-05-15 |
2016-12-29 |
Seattle Genetics Inc |
Self-Stabilizing Linker Conjugates
|
US9522940B2
(en)
|
2012-05-23 |
2016-12-20 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
|
WO2013177481A1
(en)
|
2012-05-25 |
2013-11-28 |
Immunogen, Inc. |
Benzodiazepines and conjugates thereof
|
EP2859017B1
(en)
|
2012-06-08 |
2019-02-20 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
KR102332435B1
(ko)
|
2012-06-19 |
2021-12-01 |
암브룩스, 인코포레이티드 |
항cd70 항체 약물 컨쥬게이트
|
WO2014004639A1
(en)
|
2012-06-26 |
2014-01-03 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
CA2871882A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
CN104395339A
(zh)
|
2012-06-27 |
2015-03-04 |
弗·哈夫曼-拉罗切有限公司 |
用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
|
AU2013288930A1
(en)
|
2012-07-09 |
2014-12-04 |
Genentech, Inc. |
Immunoconjugates comprising anti-CD79b antibodies
|
EP2869849A1
(en)
|
2012-07-09 |
2015-05-13 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd22 antibodies
|
MX2015000314A
(es)
|
2012-07-09 |
2015-04-10 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados.
|
BR112015000439A2
(pt)
|
2012-07-09 |
2017-12-19 |
Genentech Inc |
imunoconjugado , formulação farmacêutica e métodos de tratamento de um indivíduo e de inibição da proliferação
|
EP2885311B1
(en)
|
2012-08-18 |
2020-01-01 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
KR102355959B1
(ko)
|
2012-08-23 |
2022-01-27 |
어젠시스 인코포레이티드 |
158p1d7 단백질에 결합하는 항체 약물 컨쥬게이트(adc)
|
SG11201501464TA
(en)
|
2012-08-31 |
2015-03-30 |
Sutro Biopharma Inc |
Modified amino acids comprising an azido group
|
SI2897978T1
(sl)
|
2012-09-19 |
2017-05-31 |
Abbvie Biotherapeutics Inc. |
Postopki za identifikacijo protiteles z zmanjšano imunogenostjo
|
US10736903B2
(en)
|
2012-10-12 |
2020-08-11 |
Medimmune Limited |
Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
|
JP5993093B2
(ja)
|
2012-10-12 |
2016-09-14 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピン類およびその複合体
|
SI2906296T1
(en)
|
2012-10-12 |
2018-06-29 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
WO2014057120A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
PT2906251T
(pt)
|
2012-10-12 |
2017-12-04 |
Medimmune Ltd |
Conjugados de pirrolobenzodiazepina-anticorpo anti-cd22
|
MX364329B
(es)
|
2012-10-12 |
2019-04-23 |
Medimmune Ltd |
Conjugados del anticuerpo pirrolobenzodiazepina.
|
MX364326B
(es)
|
2012-10-12 |
2019-04-23 |
Medimmune Ltd |
Conjugados del anticuerpo pirrolobenzodiazepina - anti-psma.
|
AU2013340799B2
(en)
|
2012-11-01 |
2018-08-09 |
Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) |
An antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
|
PE20150892A1
(es)
|
2012-11-07 |
2015-06-11 |
Pfizer |
Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
|
US10131682B2
(en)
|
2012-11-24 |
2018-11-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
EP2740493A1
(en)
|
2012-12-05 |
2014-06-11 |
Institut Curie |
Conjugates of the B-subunit of Shiga toxin for anticancer therapies
|
EP2928504B1
(en)
|
2012-12-10 |
2019-02-20 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
US10226535B2
(en)
|
2012-12-10 |
2019-03-12 |
Mersana Therapeutics, Inc. |
Auristatin compounds and conjugates thereof
|
WO2014093640A1
(en)
|
2012-12-12 |
2014-06-19 |
Mersana Therapeutics,Inc. |
Hydroxy-polmer-drug-protein conjugates
|
AR094280A1
(es)
|
2012-12-21 |
2015-07-22 |
Bioalliance Cv |
Enlazantes hidrofilicos auto-inmolantes y conjugados de los mismos
|
EA031585B1
(ru)
|
2012-12-21 |
2019-01-31 |
Медимьюн Лимитед |
Пирролобензодиазепины и их конъюгаты
|
US9567340B2
(en)
|
2012-12-21 |
2017-02-14 |
Medimmune Limited |
Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
|
CA2898100C
(en)
|
2013-01-14 |
2023-10-10 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
CA2897987A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
CN103933575B
(zh)
|
2013-01-23 |
2017-09-29 |
上海新理念生物医药科技有限公司 |
一种三齿型连接子及其应用
|
ITUD20130024A1
(it)
|
2013-02-22 |
2014-08-23 |
Carlo Galli |
Aptameri per la realizzazione di dispositivi biomedicali impiantabili in tessuto e relativo metodo
|
CA2904044C
(en)
|
2013-03-13 |
2020-03-31 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
NZ712035A
(en)
|
2013-03-13 |
2019-06-28 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
SG11201507214SA
(en)
|
2013-03-13 |
2015-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
MX2015010777A
(es)
|
2013-03-14 |
2016-04-25 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-b7-h4.
|
EP2970489A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Biotechnology Ltd |
Anti-cd25 antibodies and their uses
|
TW202146054A
(zh)
|
2013-03-15 |
2021-12-16 |
德商艾伯維德國有限及兩合公司 |
抗-egfr抗體藥物結合物調配物
|
CN105377892A
(zh)
|
2013-03-15 |
2016-03-02 |
艾伯维生物技术有限公司 |
抗cd25抗体及其用途
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
AU2014232416B2
(en)
|
2013-03-15 |
2017-09-28 |
Xencor, Inc. |
Modulation of T Cells with Bispecific Antibodies and FC Fusions
|
EP2968589A1
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Antibody drug conjugate (adc) purification
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
EP3590922A1
(en)
|
2013-03-15 |
2020-01-08 |
Zymeworks Inc. |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
EP2951203B1
(en)
|
2013-03-15 |
2019-05-22 |
Xencor, Inc. |
Heterodimeric proteins
|
JP6449229B2
(ja)
|
2013-03-15 |
2019-01-09 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
Fc変異体
|
FR3005051A1
(fr)
*
|
2013-04-25 |
2014-10-31 |
Pf Medicament |
Derives de la dolastatine 10 et d'auristatines
|
AU2014262566A1
(en)
|
2013-05-08 |
2015-11-12 |
Zymeworks Inc. |
Bispecific HER2 and HER3 antigen binding constructs
|
EP3004161B1
(en)
|
2013-05-31 |
2019-10-02 |
Genentech, Inc. |
Anti-wall teichoic antibodies and conjugates
|
KR20160015227A
(ko)
|
2013-05-31 |
2016-02-12 |
제넨테크, 인크. |
항-세포벽 테이코산 항체 및 접합체
|
AU2014274982B2
(en)
|
2013-06-04 |
2019-12-05 |
Cytomx Therapeutics, Inc |
Compositions and methods for conjugating activatable antibodies
|
AR096687A1
(es)
|
2013-06-24 |
2016-01-27 |
Genentech Inc |
Anticuerpos anti-fcrh5
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
EP3013347B1
(en)
|
2013-06-27 |
2019-12-11 |
Academia Sinica |
Glycan conjugates and use thereof
|
WO2015006555A2
(en)
|
2013-07-10 |
2015-01-15 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
EP3022221B1
(en)
|
2013-07-18 |
2021-09-15 |
Taurus Biosciences, LLC |
Humanized antibodies with ultralong complementarity determining regions
|
US9925273B2
(en)
|
2013-08-01 |
2018-03-27 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to CD37 proteins
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
KR102298172B1
(ko)
|
2013-09-06 |
2021-09-06 |
아카데미아 시니카 |
변화된 글리코실 그룹을 갖는 당지질을 사용한 인간 iNKT 세포 활성화
|
EA201600252A1
(ru)
|
2013-09-12 |
2017-05-31 |
Галозим, Инк. |
Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
|
RU2016109247A
(ru)
|
2013-09-17 |
2017-10-19 |
Дженентек, Инк. |
Способы применения антител к lgr5
|
RU2016117810A
(ru)
|
2013-10-11 |
2017-11-17 |
Асана Биосайенсис, Ллк |
Конъюгаты белок-полимер-лекарственное средство
|
US9956299B2
(en)
|
2013-10-11 |
2018-05-01 |
Medimmune Limited |
Pyrrolobenzodiazepine—antibody conjugates
|
EP3054985B1
(en)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
AU2014331667B2
(en)
|
2013-10-11 |
2019-08-22 |
Biomed Valley Discoveries, Inc. |
TEM8 antibodies and their use
|
US10010624B2
(en)
|
2013-10-11 |
2018-07-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
DK3055331T3
(da)
|
2013-10-11 |
2021-03-22 |
Oxford Bio Therapeutics Ltd |
Konjugerede antistoffer mod ly75 til cancerbehandling
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
EP3054991B1
(en)
|
2013-10-11 |
2019-04-03 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
WO2015057461A2
(en)
|
2013-10-18 |
2015-04-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that specifically bind ataxia telangiectasia-mutated and rad3-related kinase phosphorylated at position 1989 and their use
|
US20160280798A1
(en)
|
2013-11-06 |
2016-09-29 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Service |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
US10196455B2
(en)
|
2013-11-07 |
2019-02-05 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Neuregulin allosteric anti-HER3 antibody
|
US10273303B2
(en)
|
2013-11-13 |
2019-04-30 |
Zymeworks Inc. |
Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
|
AU2014357292B2
(en)
|
2013-11-27 |
2020-06-25 |
Zymeworks Bc Inc. |
Bispecific antigen-binding constructs targeting HER2
|
WO2015089344A1
(en)
|
2013-12-13 |
2015-06-18 |
Genentech, Inc. |
Anti-cd33 antibodies and immunoconjugates
|
PT3083689T
(pt)
|
2013-12-17 |
2020-08-27 |
Genentech Inc |
Anticorpos anti-cd3 e métodos de utilização
|
DK3082878T3
(da)
|
2013-12-19 |
2022-12-12 |
Seagen Inc |
Methylencarbamatlinkere til anvendelse med targeterede lægemiddelkonjugater
|
SG11201610465PA
(en)
|
2013-12-19 |
2017-01-27 |
Seattle Genetics Inc |
Methylene carbamate linkers for use with targeted-drug conjugates
|
CA2935077C
(en)
|
2013-12-27 |
2022-03-15 |
Geoffrey C. Winters |
Sulfonamide-containing linkage systems for drug conjugates
|
JP6615115B2
(ja)
|
2013-12-27 |
2019-12-04 |
ザイムワークス インコーポレイティド |
Var2csa−薬物コンジュゲート
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
WO2015108998A2
(en)
|
2014-01-15 |
2015-07-23 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Cartilage targeting agents and their use
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CA2937123A1
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
BR112016015693A2
(pt)
|
2014-01-24 |
2017-10-24 |
Genentech Inc |
método para tratar um câncer de próstata e anticorpo
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN111187348A
(zh)
|
2014-02-11 |
2020-05-22 |
西雅图基因公司 |
蛋白质的选择性还原
|
AU2014384434B2
(en)
|
2014-02-28 |
2016-11-03 |
Hangzhou Dac Biotech Co., Ltd |
Charged linkers and their uses for conjugation
|
IL295906A
(en)
|
2014-03-21 |
2022-10-01 |
Abbvie Inc |
Antibodies against egfr and drug antibody conjugates
|
CN106415244B
(zh)
|
2014-03-27 |
2020-04-24 |
中央研究院 |
反应性标记化合物及其用途
|
BR112016022385A2
(pt)
|
2014-03-28 |
2018-06-19 |
Xencor, Inc |
anticorpos específicos que se ligam a cd38 e cd3
|
US9260478B2
(en)
|
2014-04-04 |
2016-02-16 |
Shanghui Hu |
Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis
|
MX2016012830A
(es)
|
2014-04-11 |
2017-01-05 |
Medimmune Llc |
Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
FR3020063A1
(fr)
|
2014-04-16 |
2015-10-23 |
Gamamabs Pharma |
Anticorps humain anti-her4
|
KR20230164192A
(ko)
|
2014-05-06 |
2023-12-01 |
제넨테크, 인크. |
포유동물 세포를 사용한 이종다량체 단백질의 생산
|
JP2017522861A
(ja)
|
2014-05-22 |
2017-08-17 |
ジェネンテック, インコーポレイテッド |
抗gpc3抗体及びイムノコンジュゲート
|
KR20220151036A
(ko)
|
2014-05-27 |
2022-11-11 |
아카데미아 시니카 |
항-cd20 글리코항체 및 이의 용도
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
EP3149045B1
(en)
|
2014-05-27 |
2023-01-18 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
WO2015184002A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-her2 glycoantibodies and uses thereof
|
US20170190735A1
(en)
*
|
2014-05-28 |
2017-07-06 |
Agensys, Inc. |
Derivatives of dolaproine-dolaisoleuine peptides
|
WO2015184001A1
(en)
|
2014-05-28 |
2015-12-03 |
Academia Sinica |
Anti-tnf-alpha glycoantibodies and uses thereof
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
CA2952876A1
(en)
|
2014-06-20 |
2015-12-23 |
Bioalliance C.V. |
Anti-folate receptor alpha (fra) antibody-drug conjugates and methods of using thereof
|
EP3160513B1
(en)
|
2014-06-30 |
2020-02-12 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
WO2016008112A1
(en)
|
2014-07-16 |
2016-01-21 |
Medshine Discovery Inc. |
Linkers and application towards adc thereof
|
AU2015292326A1
(en)
|
2014-07-24 |
2017-02-23 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
ES2925224T3
(es)
|
2014-07-31 |
2022-10-14 |
Us Gov Health & Human Services |
Anticuerpos monoclonales humanos contra EphA4 y su uso
|
KR20230172625A
(ko)
|
2014-08-28 |
2023-12-22 |
바이오아트라, 인코퍼레이티드 |
변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
|
JP6899321B2
(ja)
|
2014-09-08 |
2021-07-07 |
アカデミア シニカAcademia Sinica |
糖脂質を使用するヒトiNKT細胞活性化
|
WO2016037644A1
(en)
|
2014-09-10 |
2016-03-17 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
SG10202006505UA
(en)
|
2014-09-11 |
2020-08-28 |
Seattle Genetics Inc |
Targeted delivery of tertiary amine-containing drug substances
|
TW201625690A
(zh)
|
2014-09-12 |
2016-07-16 |
建南德克公司 |
抗-cll-1抗體及免疫結合物
|
CN113698485A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
CN107108724A
(zh)
|
2014-09-12 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
半胱氨酸改造抗体和缀合物
|
SG11201701623UA
(en)
|
2014-09-12 |
2017-03-30 |
Genentech Inc |
Anti-her2 antibodies and immunoconjugates
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
CN113416229A
(zh)
|
2014-09-17 |
2021-09-21 |
酵活有限公司 |
细胞毒性和抗有丝分裂化合物、及其使用方法
|
RU2727663C2
(ru)
|
2014-09-17 |
2020-07-22 |
Дженентек, Инк. |
Иммуноконъюгаты, содержащие антитела против her2 и пирролбензодиазепины
|
HRP20200924T8
(hr)
|
2014-09-23 |
2023-07-21 |
F. Hoffmann - La Roche Ag |
Postupak primjene imunokonjugata anti-cd79b
|
CA2962783A1
(en)
|
2014-10-01 |
2016-04-07 |
Medimmune, Llc |
Method of conjugating a polypeptide
|
WO2016073789A2
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
CA2968447A1
(en)
|
2014-11-25 |
2016-06-02 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates and their use to treat neoplasms
|
TN2017000223A1
(en)
|
2014-11-26 |
2018-10-19 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
EA037065B1
(ru)
|
2014-11-26 |
2021-02-01 |
Ксенкор, Инк. |
Гетеродимерные антитела, связывающие cd3 и cd38
|
US20170355779A1
(en)
|
2014-11-27 |
2017-12-14 |
Zymeworks Inc. |
Methods of using bispecific antigen-binding constructs targeting her2
|
KR20170086536A
(ko)
|
2014-12-03 |
2017-07-26 |
제넨테크, 인크. |
항-스타필로코커스 아우레우스 항체 리파마이신 접합체 및 이의 용도
|
ES2764111T3
(es)
|
2014-12-03 |
2020-06-02 |
Hoffmann La Roche |
Anticuerpos multiespecíficos
|
MX2017007231A
(es)
|
2014-12-03 |
2017-11-08 |
Genentech Inc |
Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos.
|
JP6864953B2
(ja)
|
2014-12-09 |
2021-04-28 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Axlに対するヒトモノクローナル抗体
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CA2972731A1
(en)
|
2015-01-24 |
2016-07-28 |
Chi-Huey Wong |
Cancer markers and methods of use thereof
|
CA2972072A1
(en)
|
2015-01-24 |
2016-07-28 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
JP2018512597A
(ja)
|
2015-02-04 |
2018-05-17 |
ジェネンテック, インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
KR20170140180A
(ko)
|
2015-02-24 |
2017-12-20 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
|
AU2016226083A1
(en)
|
2015-03-05 |
2017-10-12 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
EP3268038B1
(en)
|
2015-03-09 |
2021-05-05 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to flt3 proteins
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
GB201506389D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
KR102668727B1
(ko)
|
2015-04-24 |
2024-05-28 |
제넨테크, 인크. |
다중특이적 항원-결합 단백질
|
EP3292222A4
(en)
|
2015-05-06 |
2018-10-17 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen binding fibronectin type iii domains
|
EP3091033A1
(en)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3 antibodies and uses thereof
|
EP3295171A1
(en)
|
2015-05-12 |
2018-03-21 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and kits for labeling, detection and isolation of foxp3+ regulatory t cells, isolated population of foxp3+ regulatory t cells thus obtained and uses thereof
|
EP3298044B1
(en)
|
2015-05-22 |
2021-08-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
|
WO2016189091A1
(en)
|
2015-05-26 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas
|
WO2016189118A1
(en)
|
2015-05-28 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
|
CN106279352B
(zh)
|
2015-05-29 |
2020-05-22 |
上海新理念生物医药科技有限公司 |
海兔毒素10的衍生物及其应用
|
ES2961346T3
(es)
|
2015-06-12 |
2024-03-11 |
Lentigen Tech Inc |
Procedimiento para tratar cáncer con células T modificadas genéticamente
|
US10323094B2
(en)
|
2015-06-16 |
2019-06-18 |
Genentech, Inc. |
Humanized and affinity matured antibodies to FcRH5 and methods of use
|
EP3954394A1
(en)
|
2015-06-19 |
2022-02-16 |
Centurion BioPharma Corporation |
Delivery systems for controlled drug release
|
EP3319936A4
(en)
|
2015-07-12 |
2019-02-06 |
Suzhou M-conj Biotech Co., Ltd. |
PLACES OF CONDUCT FOR THE CONJUGATION OF CELL BINDING MOLECULES
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
US10722593B2
(en)
|
2015-10-02 |
2020-07-28 |
Sirenas Llc |
Anti-cancer compounds and conjugates thereof
|
AU2016335750B2
(en)
|
2015-10-07 |
2023-05-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
|
ES2778651T3
(es)
|
2015-10-09 |
2020-08-11 |
Miltenyi Biotec Technology Inc |
Receptores de antígeno quimérico y métodos de uso
|
WO2017060397A1
(en)
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from melanoma metastases
|
WO2017064034A1
(en)
|
2015-10-12 |
2017-04-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
An agent capable of depleting cd8 t cells for the treatment of myocardial infarction or acute myocardial infarction
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
WO2017067944A1
(en)
|
2015-10-19 |
2017-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from triple negative breast cancer
|
CN106729743B
(zh)
|
2015-11-23 |
2021-09-21 |
四川科伦博泰生物医药股份有限公司 |
抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
|
JP2019501131A
(ja)
|
2015-12-04 |
2019-01-17 |
シアトル ジェネティックス, インコーポレイテッド |
四級化チューブリシン化合物の複合体
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
CA3007030A1
(en)
|
2015-12-07 |
2017-06-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
MA44072A
(fr)
|
2015-12-17 |
2018-10-24 |
Janssen Biotech Inc |
Anticorps se liant spécifiquement à hla-dr et leurs utilisations
|
JP7078536B2
(ja)
|
2016-01-08 |
2022-05-31 |
アルトゥルバイオ, インコーポレイテッド |
四価抗psgl-1抗体とその使用
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
AU2017212484C1
(en)
|
2016-01-27 |
2020-11-05 |
Medimmune, Llc |
Methods for preparing antibodies with a defined glycosylation pattern
|
SG11201806419RA
(en)
|
2016-01-27 |
2018-08-30 |
Sutro Biopharma Inc |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
US11191821B2
(en)
|
2016-02-27 |
2021-12-07 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Peptide vaccine formulations and use thereof for inducing an immune response
|
EP3423112A4
(en)
|
2016-02-29 |
2020-02-26 |
Madrigal Pharmaceuticals, Inc. |
HSP9 INHIBITOR-ACTIVE CONJUGATES
|
WO2017156192A1
(en)
|
2016-03-08 |
2017-09-14 |
Academia Sinica |
Methods for modular synthesis of n-glycans and arrays thereof
|
MA45324A
(fr)
|
2016-03-15 |
2019-01-23 |
Seattle Genetics Inc |
Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
|
JP7137474B2
(ja)
|
2016-03-15 |
2022-09-14 |
メルサナ セラピューティクス,インコーポレイティド |
NaPi2b標的化抗体-薬物コンジュゲート及びその使用方法
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
US10851160B2
(en)
|
2016-03-22 |
2020-12-01 |
Institut National De La Sante Et De La Recherche Medicale |
Humanized anti-claudin-1 antibodies and uses thereof
|
KR20180134351A
(ko)
|
2016-03-25 |
2018-12-18 |
시애틀 지네틱스, 인크. |
페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
|
EP3438118B1
(en)
|
2016-03-29 |
2023-03-29 |
Toray Industries, Inc. |
Peptide derivative and use thereof
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
UA127341C2
(uk)
|
2016-04-15 |
2023-07-26 |
Мекроудженікс, Інк. |
Виділена b7-н3-зв'язувальна молекула
|
KR102459684B1
(ko)
|
2016-04-15 |
2022-10-26 |
바이오아트라, 인코퍼레이티드 |
항 Axl항체 및 이의 면역접합체와 이것들의 용도
|
CN109071634A
(zh)
|
2016-04-26 |
2018-12-21 |
R.P.谢勒技术有限责任公司 |
抗体偶联物及其制备和使用方法
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
KR20230044567A
(ko)
|
2016-05-13 |
2023-04-04 |
바이오아트라, 인코퍼레이티드 |
항 ror2 항체, 항체 단편 및 이의 면역접합체와 이것들의 용도
|
WO2017205741A1
(en)
|
2016-05-27 |
2017-11-30 |
Genentech, Inc. |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
CA3027044A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
CN109641962A
(zh)
|
2016-06-08 |
2019-04-16 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
TWI762487B
(zh)
|
2016-06-08 |
2022-05-01 |
美商艾伯維有限公司 |
抗-b7-h3抗體及抗體藥物結合物
|
CA3027033A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
CA3027046A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
CA3026151A1
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
EP3474901A1
(en)
|
2016-06-27 |
2019-05-01 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
JP7021127B2
(ja)
|
2016-06-28 |
2022-02-16 |
ゼンコア インコーポレイテッド |
ソマトスタチン受容体2に結合するヘテロ二量体抗体
|
AU2017310436B2
(en)
|
2016-08-09 |
2022-08-25 |
Seagen Inc. |
Drug conjugates with self-stabilizing linkers having improved physiochemical properties
|
TWI764917B
(zh)
|
2016-08-22 |
2022-05-21 |
醣基生醫股份有限公司 |
抗體、結合片段及使用方法
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
US11254705B2
(en)
|
2016-09-02 |
2022-02-22 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
US11453712B2
(en)
|
2016-09-02 |
2022-09-27 |
Lentigen Technology Inc. |
Compositions and methods for treating cancer with DuoCARs
|
CN107857798B
(zh)
*
|
2016-09-22 |
2021-03-23 |
联宁(苏州)生物制药有限公司 |
一种用于抗体药物偶联物的毒素及其制备方法
|
US10517958B2
(en)
|
2016-10-04 |
2019-12-31 |
Zymeworks Inc. |
Compositions and methods for the treatment of platinum-drug resistant cancer
|
AU2017342560B2
(en)
|
2016-10-14 |
2022-03-17 |
Xencor, Inc. |
IL15/IL15Ralpha heterodimeric Fc-fusion proteins
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
AU2017351764A1
(en)
|
2016-10-25 |
2019-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Monoclonal antibodies binding to the CD160 transmembrane isoform
|
KR20220147720A
(ko)
|
2016-11-14 |
2022-11-03 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
EP3468991A1
(en)
|
2016-11-21 |
2019-04-17 |
cureab GmbH |
Anti-gp73 antibodies and immunoconjugates
|
JP6951441B2
(ja)
|
2016-11-23 |
2021-10-20 |
イーライ リリー アンド カンパニー |
Met抗体薬物複合体
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
KR102085798B1
(ko)
|
2016-12-28 |
2020-03-06 |
주식회사 인투셀 |
베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
|
SG11201906200WA
(en)
|
2017-01-06 |
2019-08-27 |
Avidity Biosciences Llc |
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
|
EP3565830B1
(en)
|
2017-01-09 |
2021-03-10 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-mesothelin immunotherapy
|
DK3544636T3
(da)
|
2017-02-08 |
2021-05-10 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepin-antistof-konjugater
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
EP3579872A1
(en)
|
2017-02-10 |
2019-12-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
|
TW201834697A
(zh)
|
2017-02-28 |
2018-10-01 |
美商梅爾莎納醫療公司 |
Her2標靶抗體-藥物結合物之組合療法
|
WO2018175994A1
(en)
|
2017-03-24 |
2018-09-27 |
Seattle Genetics, Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
CA3057838A1
(en)
|
2017-03-24 |
2018-09-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd33 immunotherapy
|
RS63502B1
(sr)
|
2017-04-18 |
2022-09-30 |
Medimmune Ltd |
Konjugati pirolobenzodiazepina
|
WO2018195302A1
(en)
|
2017-04-19 |
2018-10-25 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
CA3057748A1
(en)
|
2017-04-20 |
2018-10-25 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
WO2018209239A1
(en)
|
2017-05-11 |
2018-11-15 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
WO2018226580A2
(en)
|
2017-06-05 |
2018-12-13 |
Janssen Biotech, Inc. |
Antibodies that specifically bind pd-1 and methods of use
|
UA127900C2
(uk)
|
2017-06-14 |
2024-02-07 |
Ейдісі Терапьютікс Са |
Схема дозування для введення adc до cd19
|
WO2018237262A1
(en)
|
2017-06-22 |
2018-12-27 |
Mersana Therapeutics, Inc. |
METHODS FOR PRODUCING POLYMERIC MATRICES TRANSPORTING MEDICAMENTS, AND PROTEIN-POLYMER-MEDICINE CONJUGATES
|
US20210403573A1
(en)
|
2017-06-22 |
2021-12-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
|
AU2018289581A1
(en)
|
2017-06-23 |
2020-01-16 |
VelosBio Inc. |
ROR1 antibody immunoconjugates
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
EP3658588A1
(en)
|
2017-07-26 |
2020-06-03 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
CA3071624A1
(en)
|
2017-07-31 |
2019-02-07 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
|
WO2019034764A1
(en)
|
2017-08-18 |
2019-02-21 |
Medimmune Limited |
CONJUGATES OF PYRROLOBENZODIAZEPINE
|
JP7250766B2
(ja)
|
2017-08-25 |
2023-04-03 |
ヤンセン バイオテツク,インコーポレーテツド |
FCγRII結合フィブロネクチンIII型ドメイン、それらのコンジュゲート、及びそれらを含む多重特異性分子
|
EP4279086A3
(en)
|
2017-09-15 |
2024-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19 immunotherapy
|
WO2019055909A1
(en)
|
2017-09-18 |
2019-03-21 |
Sutro Biopharma, Inc. |
ALPHA ANTI-FOLATE ANTIBODY-RECEPTOR CONJUGATES AND USES THEREOF
|
CA3077213A1
(en)
|
2017-10-04 |
2019-04-11 |
Avidity Biosciences, Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
CA3078737A1
(en)
|
2017-10-11 |
2019-04-18 |
Seattle Genetics, Inc. |
Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
EP3697426B1
(en)
|
2017-10-16 |
2023-07-26 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd22 immunotherapy
|
MA50862A
(fr)
|
2017-11-01 |
2020-09-09 |
Seattle Genetics Inc |
Procédés de réduction des effets secondaires d'une thérapie par conjugués médicament anticorps anti-cd30
|
CN112272563A
(zh)
|
2017-11-08 |
2021-01-26 |
Xencor股份有限公司 |
使用新颖抗pd-1序列的双特异性和单特异性抗体
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
EP4344747A3
(en)
*
|
2017-11-30 |
2024-07-03 |
LadRx Corporation |
Albumin-binding prodrugs of auristatin e derivatives
|
JP7442821B2
(ja)
|
2017-11-30 |
2024-03-05 |
センチュリオン バイオファーマ コーポレイション |
メイタンシノイド系薬物送達システム
|
US11576981B2
(en)
|
2017-12-06 |
2023-02-14 |
Ontario Institute For Cancer Research (Oicr) |
Acyl hydrazone linkers, methods and uses thereof
|
KR102443358B1
(ko)
|
2017-12-06 |
2022-09-14 |
어비디티 바이오사이언시스 인크. |
근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
US12006356B2
(en)
|
2017-12-15 |
2024-06-11 |
Juno Therapeutics, Inc. |
Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
|
US11319355B2
(en)
|
2017-12-19 |
2022-05-03 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
EP3728307A4
(en)
|
2017-12-20 |
2021-05-19 |
Lentigen Technology, Inc. |
COMPOSITIONS AND METHODS OF TREATMENT OF HIV / AIDS WITH IMMUNOTHERAPY
|
EP3728273A4
(en)
|
2017-12-22 |
2021-12-29 |
Ontario Institute for Cancer Research (OICR) |
Heterocyclic acyl hydrazone linkers, methods and uses thereof
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
RS64690B1
(sr)
|
2018-03-13 |
2023-11-30 |
Zymeworks Bc Inc |
Konjugati biparatopskog anti-her2 antitela i leka i postupci za njihovu upotrebu
|
MX2020009842A
(es)
|
2018-03-23 |
2020-10-15 |
Seattle Genetics Inc |
Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido.
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
JP6761506B2
(ja)
|
2018-04-13 |
2020-09-23 |
ジェネンテック, インコーポレイテッド |
安定した抗cd79bイムノコンジュゲート製剤
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
IL−15/IL−15RA Fc融合タンパク質およびTIM−3抗原結合ドメインを含む、TIM−3標的化ヘテロ二量体融合タンパク質
|
WO2019204665A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
WO2019212356A1
(en)
|
2018-05-04 |
2019-11-07 |
Tagworks Pharmaceuticals B .V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
CA3099421A1
(en)
|
2018-05-04 |
2019-11-07 |
Tagworks Pharmaceuticals B.V. |
Compounds comprising a linker for increasing transcyclooctene stability
|
CN112739716A
(zh)
|
2018-05-07 |
2021-04-30 |
展马博联合股份有限公司 |
使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法
|
KR20210005617A
(ko)
|
2018-05-07 |
2021-01-14 |
젠맵 에이/에스 |
항-pd-1 항체와 항-조직 인자 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법
|
KR20210027436A
(ko)
|
2018-06-29 |
2021-03-10 |
베링거 인겔하임 인터내셔날 게엠베하 |
자가면역 질환을 치료하는데 사용하기 위한 항-cd40 항체
|
KR20210028204A
(ko)
|
2018-07-02 |
2021-03-11 |
암젠 인크 |
항-steap1 항원 결합 단백질
|
AU2019301138A1
(en)
|
2018-07-11 |
2021-02-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibody for the detection of the antiretroviral drug emtricitabine (FTC, 2',3'-dideoxy-5-fluoro-3'-thiacytidine)
|
CA3107383A1
(en)
|
2018-07-23 |
2020-01-30 |
Magenta Therapeutics, Inc. |
Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
|
JP2022500454A
(ja)
|
2018-09-17 |
2022-01-04 |
ストロ バイオファーマ インコーポレーテッド |
抗葉酸受容体抗体コンジュゲートによる併用療法
|
JP2022511337A
(ja)
|
2018-09-19 |
2022-01-31 |
インサーム (インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル) |
免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
|
AU2019343184A1
(en)
|
2018-09-20 |
2021-04-15 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
EP3626265A1
(en)
|
2018-09-21 |
2020-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-human cd45rc antibodies and uses thereof
|
EP3856235A2
(en)
|
2018-09-26 |
2021-08-04 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
CA3114922A1
(en)
|
2018-10-01 |
2020-04-09 |
Seagen Inc. |
Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy
|
JP2022503959A
(ja)
|
2018-10-03 |
2022-01-12 |
ゼンコア インコーポレイテッド |
Il-12ヘテロ二量体fc-融合タンパク質
|
KR20210084546A
(ko)
|
2018-10-29 |
2021-07-07 |
메르사나 테라퓨틱스, 인코포레이티드 |
펩티드 함유 링커를 갖는 시스테인 조작된 항체-약물 접합체
|
EA202190734A1
(ru)
|
2018-10-30 |
2021-10-15 |
Генмаб А/С |
Способы лечения рака с помощью комбинации антитела против vegf и конъюгата антитело против тканевого фактора-лекарственное средство
|
JP2022512860A
(ja)
|
2018-11-06 |
2022-02-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
白血病幹細胞を根絶することによる急性骨髄性白血病の治療のための方法および医薬組成物
|
WO2020113108A1
(en)
|
2018-11-30 |
2020-06-04 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd38 immunotherapy
|
MX2021006573A
(es)
|
2018-12-06 |
2021-07-15 |
Genentech Inc |
Tratamiento conjunto de linfoma difuso de linfocitos b grandes que comprende un inmunoconjugado anti-cd79b, un agente alquilante y un anticuerpo anti-cd20.
|
CN113227119A
(zh)
|
2018-12-10 |
2021-08-06 |
基因泰克公司 |
用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
|
JP2022516408A
(ja)
|
2018-12-14 |
2022-02-28 |
インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) |
単離されたMHC由来ヒトペプチドおよびCD8+CD45RClowTregの抑制機能を刺激し、かつ活性化するためのその使用
|
WO2020127411A1
(en)
|
2018-12-19 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
|
WO2020127968A1
(en)
|
2018-12-20 |
2020-06-25 |
Marino Stephen F |
Protein-drug conjugate comprising a monomeric form of proteinase 3
|
EP3898693A4
(en)
|
2018-12-21 |
2022-09-21 |
Avidity Biosciences, Inc. |
ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
KR20210124308A
(ko)
|
2019-01-30 |
2021-10-14 |
트루바인딩 아이엔씨. |
항-gal3 항체 및 이의 용도
|
WO2020180726A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
JP2022524507A
(ja)
|
2019-03-06 |
2022-05-06 |
レンティジェン・テクノロジー・インコーポレイテッド |
自己駆動型キメラ抗原受容体を用いてがんを処置するための組成物および方法
|
EP3941944A4
(en)
|
2019-03-20 |
2022-11-30 |
The Regents of the University of California |
B-SPECIFIC CLAUDIN-6 ANTIBODIES
|
BR112021018608A2
(pt)
|
2019-03-20 |
2021-11-23 |
Univ California |
Anticorpos para claudina-6 e conjugados de fármaco
|
WO2020227105A1
(en)
|
2019-05-03 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
AU2020275415A1
(en)
|
2019-05-14 |
2021-11-25 |
Genentech, Inc. |
Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma
|
CA3140102A1
(en)
|
2019-05-30 |
2020-12-03 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with anti-bcma immunotherapy
|
WO2020247054A1
(en)
|
2019-06-05 |
2020-12-10 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
JP2022535911A
(ja)
|
2019-06-06 |
2022-08-10 |
アビディティー バイオサイエンシーズ,インク. |
Unaアミダイトおよびその使用
|
EP3980436A4
(en)
|
2019-06-06 |
2023-12-20 |
Avidity Biosciences, Inc. |
NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
|
GB201908128D0
(en)
|
2019-06-07 |
2019-07-24 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
WO2020256546A1
(en)
|
2019-06-17 |
2020-12-24 |
Tagworks Pharmaceuticals B.V. |
Compounds for fast and efficient click release
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
EP3994173A1
(en)
|
2019-07-02 |
2022-05-11 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
WO2021007338A1
(en)
|
2019-07-08 |
2021-01-14 |
Imcare Biotech, Llc. |
Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
|
CA3147735A1
(en)
|
2019-07-26 |
2021-02-04 |
Janssen Biotech, Inc. |
Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
|
EP4013788A1
(en)
|
2019-08-12 |
2022-06-22 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
|
EP4013783A1
(en)
|
2019-08-15 |
2022-06-22 |
Janssen Biotech, Inc. |
Materials and methods for improved single chain variable fragments
|
US20240043512A1
(en)
|
2019-09-11 |
2024-02-08 |
Imcare Biotech, Llc |
Epitopes of anti-serine protease inhibitor kazal (spik) antibodies
|
AU2020348876A1
(en)
|
2019-09-19 |
2022-04-07 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
WO2021062122A1
(en)
|
2019-09-25 |
2021-04-01 |
Seagen Inc. |
Combination anti-cd30 adc, anti-pd-1 and chemotherapeutic for treatment of hematopoietic cancers
|
US20220363776A1
(en)
|
2019-10-04 |
2022-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
KR20220086618A
(ko)
|
2019-10-18 |
2022-06-23 |
제넨테크, 인크. |
미만성 거대 B-세포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
EP3812008A1
(en)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-competitive antagonist antibody
|
WO2021080608A1
(en)
|
2019-10-25 |
2021-04-29 |
Medimmune, Llc |
Branched moiety for use in conjugates
|
AU2020380732A1
(en)
|
2019-11-07 |
2022-06-02 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
TW202131954A
(zh)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
利用鉑類劑與抗組織因子抗體-藥物共軛體之組合來治療癌症之方法
|
IL293751A
(en)
|
2019-12-18 |
2022-08-01 |
Teneofour Inc |
Heavy chain antibodies that bind to cd38
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
BR112022018176A2
(pt)
|
2020-03-13 |
2022-12-06 |
Janssen Biotech Inc |
Materiais e métodos para ligação de siglec-3/cd33
|
IL310900A
(en)
|
2020-03-19 |
2024-04-01 |
Avidity Biosciences Inc |
Preparations and methods for the treatment of facial, back and arm muscle atrophy
|
WO2021195469A1
(en)
|
2020-03-27 |
2021-09-30 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle dystrophy
|
BR112022021441A2
(pt)
|
2020-04-24 |
2022-12-13 |
Genentech Inc |
Métodos para tratar linfoma folicular e linfoma difuso de grandes células b e kits
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
CA3182333A1
(en)
|
2020-05-20 |
2021-11-25 |
Institut Curie |
Single domain antibodies and their use in cancer therapies
|
EP4157459A1
(en)
|
2020-05-27 |
2023-04-05 |
Janssen Biotech, Inc. |
Proteins comprising cd3 antigen binding domains and uses thereof
|
EP4161653A1
(en)
|
2020-06-03 |
2023-04-12 |
Bionecure Therapeutics, Inc. |
Trophoblast cell-surface antigen-2 (trop-2) antibodies
|
WO2021262723A1
(en)
|
2020-06-22 |
2021-12-30 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
|
MX2022015375A
(es)
|
2020-06-29 |
2023-01-16 |
Genmab As |
Conjugados de farmaco-anticuerpo anti-factor de tejido y su uso en el tratamiento de cancer.
|
US20230405138A1
(en)
|
2020-07-27 |
2023-12-21 |
Tuojie Biotech (Shanghai) Co., Ltd. |
Anti-cd79b antibody-drug conjugate, and preparation method therefor and pharmaceutical use thereof
|
JP2023536818A
(ja)
|
2020-07-29 |
2023-08-30 |
ヤンセン バイオテツク,インコーポレーテツド |
Hla-g抗原結合ドメインを含むタンパク質及びそれらの使用
|
US20230323299A1
(en)
|
2020-08-03 |
2023-10-12 |
Inserm (Institut National De La Santé Et De La Recherch Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
US11919958B2
(en)
|
2020-08-19 |
2024-03-05 |
Xencor, Inc. |
Anti-CD28 compositions
|
CN112062855A
(zh)
|
2020-08-26 |
2020-12-11 |
康诺亚生物医药科技(成都)有限公司 |
一种含有衔接器的药物治疗剂的开发和应用
|
CA3193273A1
(en)
|
2020-08-27 |
2022-03-03 |
Enosi Therapeutics Corporation |
Methods and compositions to treat autoimmune diseases and cancer
|
US20220089759A1
(en)
|
2020-09-21 |
2022-03-24 |
Boehringer Ingelheim International Gmbh |
Use of anti-cd40 antibodies for treatment of inflammatory conditions
|
US11926667B2
(en)
|
2020-10-13 |
2024-03-12 |
Janssen Biotech, Inc. |
Bioengineered T cell mediated immunity, materials and other methods for modulating cluster of differentiation IV and/or VIII
|
WO2022079270A1
(en)
|
2020-10-16 |
2022-04-21 |
Université D'aix-Marseille |
Anti-gpc4 single domain antibodies
|
TW202233672A
(zh)
|
2020-10-22 |
2022-09-01 |
美商健生生物科技公司 |
包括類δ配體3(DLL3)抗原結合區之蛋白質及其用途
|
WO2022099026A1
(en)
|
2020-11-05 |
2022-05-12 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
CA3197167A1
(en)
|
2020-11-09 |
2022-05-12 |
He Xu |
Antibody drug conjugates
|
CN114524878A
(zh)
|
2020-11-23 |
2022-05-24 |
康诺亚生物医药科技(成都)有限公司 |
一种双特异性抗体及其用途
|
CN114573703A
(zh)
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技(成都)有限公司 |
一种t细胞衔接器治疗剂的开发和应用
|
CN114573702A
(zh)
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技(成都)有限公司 |
一种新型肿瘤衔接器治疗药物的开发和应用
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
CN114685657A
(zh)
|
2020-12-31 |
2022-07-01 |
康诺亚生物医药科技(成都)有限公司 |
一种功能增强型抗体阻断剂的开发及其应用
|
IL304031A
(en)
|
2021-01-14 |
2023-08-01 |
Inst Curie |
Variants of single-domain HER2 antibodies and their chimeric antigenic receptors
|
UY39610A
(es)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
US20240101717A1
(en)
|
2021-01-22 |
2024-03-28 |
Bionecure Therapeutics, Inc. |
Anti-her-2/trop-2 constructs and uses thereof
|
MX2023008803A
(es)
|
2021-01-27 |
2023-08-04 |
Janssen Biotech Inc |
Inmunoconjugados que comprenden dominios de union al antigeno de la peptidasa 2 relacionada con la calicreina y sus usos.
|
MX2023009497A
(es)
|
2021-02-15 |
2023-08-23 |
Takeda Pharmaceuticals Co |
Composiciones y metodos de terapia celular para modular la se?alizacion del factor de crecimiento transformador-beta (tgf-beta).
|
AU2022232375A1
(en)
|
2021-03-09 |
2023-09-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Cd3及びgpc3に結合するヘテロ二量体抗体
|
BR112023018676A2
(pt)
|
2021-03-18 |
2023-10-10 |
Seagen Inc |
Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
|
JP2024511360A
(ja)
|
2021-03-18 |
2024-03-13 |
シージェン インコーポレイテッド |
生体活性化合物の内部移行複合体からの選択的薬物放出
|
JP2024512567A
(ja)
|
2021-03-23 |
2024-03-19 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) |
T細胞リンパ腫の診断および治療方法
|
TW202304986A
(zh)
|
2021-03-24 |
2023-02-01 |
美商健生生物科技公司 |
靶向cd22及cd79b的抗體
|
IL306132A
(en)
|
2021-03-24 |
2023-11-01 |
Janssen Biotech Inc |
Proteins containing CD3 antigen binding sites and uses thereof
|
CA3214118A1
(en)
*
|
2021-03-31 |
2022-10-06 |
Remegen Co., Ltd. |
Preparation and purification process of monomethyl auristain e compound
|
EP4320153A1
(en)
|
2021-04-09 |
2024-02-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
JP2024518709A
(ja)
|
2021-04-10 |
2024-05-02 |
プロファウンドバイオ ユーエス カンパニー |
Folr1結合剤、そのコンジュゲートおよびこれを使用する方法
|
AU2022262644A1
(en)
|
2021-04-23 |
2023-11-09 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
AR125490A1
(es)
|
2021-04-30 |
2023-07-19 |
Celgene Corp |
Terapias de combinación que utilizan un anticuerpo anti-bcma conjugado a fármaco (adc) en combinación con un inhibidor de gamma secretasa (gsi)
|
WO2022241446A1
(en)
|
2021-05-12 |
2022-11-17 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
EP4347656A1
(en)
|
2021-05-28 |
2024-04-10 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapies for treating cancer
|
WO2022271987A1
(en)
|
2021-06-23 |
2022-12-29 |
TeneoFour, Inc. |
Anti-cd38 antibodies and epitopes of same
|
AU2022304582A1
(en)
|
2021-06-29 |
2024-02-01 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
WO2023288252A1
(en)
|
2021-07-13 |
2023-01-19 |
Truebinding, Inc. |
Methods of preventing protein aggregation
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
US20230099756A1
(en)
|
2021-08-07 |
2023-03-30 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
CN118119409A
(zh)
|
2021-09-03 |
2024-05-31 |
东丽株式会社 |
癌的治疗和/或预防用药物组合物
|
WO2023031445A2
(en)
|
2021-09-06 |
2023-03-09 |
Veraxa Biotech Gmbh |
Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
|
CA3231944A1
(en)
|
2021-09-16 |
2023-03-23 |
Carole GUILLONNEAU |
Anti-human cd45rc binding domains and uses thereof
|
KR20240055874A
(ko)
|
2021-09-16 |
2024-04-29 |
어비디티 바이오사이언시스 인크. |
안면견갑상완 근이영양증을 치료하는 조성물 및 방법
|
WO2023046322A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
WO2023057893A1
(en)
|
2021-10-05 |
2023-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapies for treating cancer
|
CA3238167A1
(en)
|
2021-11-19 |
2023-05-25 |
Maria Leia Smith |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
CA3239224A1
(en)
|
2021-11-22 |
2023-05-25 |
Janssen Biotech, Inc. |
Compositions comprising enhanced multispecific binding agents for an immune response
|
EP4186529A1
(en)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
WO2023094525A1
(en)
|
2021-11-25 |
2023-06-01 |
Veraxa Biotech Gmbh |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
WO2023104941A1
(en)
|
2021-12-08 |
2023-06-15 |
European Molecular Biology Laboratory |
Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
WO2023122347A2
(en)
|
2021-12-23 |
2023-06-29 |
Mirecule, Inc. |
Compositions for delivery of polynucleotides
|
WO2023144723A1
(en)
|
2022-01-26 |
2023-08-03 |
Janssen Biotech, Inc. |
Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
WO2023158305A1
(en)
|
2022-02-15 |
2023-08-24 |
Tagworks Pharmaceuticals B.V. |
Masked il12 protein
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
WO2023198648A1
(en)
|
2022-04-11 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
TW202408583A
(zh)
|
2022-05-06 |
2024-03-01 |
丹麥商珍美寶股份有限公司 |
使用抗組織因子抗體-藥物共軛體以治療癌症之方法
|
WO2024006542A1
(en)
|
2022-06-30 |
2024-01-04 |
Sutro Biopharma, Inc. |
Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
WO2024013724A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody-drug conjugates
|
WO2024018046A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
US20240075142A1
(en)
|
2022-08-26 |
2024-03-07 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy
|
WO2024079192A1
(en)
|
2022-10-12 |
2024-04-18 |
Institut National de la Santé et de la Recherche Médicale |
Cd81 as a biomarker and biotarget in t-cell malignancies
|
WO2024080872A1
(en)
|
2022-10-12 |
2024-04-18 |
Tagworks Pharmaceuticals B.V. |
Strained bicyclononenes
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
WO2024108178A1
(en)
|
2022-11-18 |
2024-05-23 |
Genentech, Inc. |
Signal amplification and multiplexing using mass tags for ia-lc-ms/ms based assays
|
WO2024129628A1
(en)
|
2022-12-14 |
2024-06-20 |
Merck Sharp & Dohme Llc |
Auristatin linker-payloads, pharmaceutical compositions, and uses thereof
|